Key facts
- ClostraBio’s last known valuation is $16.0M (Sep 2022).
- It has raised $14.2M across 1 recorded rounds; the latest was Early Stage VC ($9.9M) in Sep 2022.
- Notable investors include Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Mansueto Office, Angela Oakey, Daniel Oakey, New Venture Challenge — 10 tracked in total.
- ClostraBio has filed 1 Form D with the SEC, most recently Sep 2022 ($9.9M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ClostraBio
Funding rounds
1 roundsAbout ClostraBio
Developer of biopharmaceuticals intended to offer therapeutics for food allergies. The company's technology specializes in developing microbiome-modulating therapeutics and commercializing small-molecule formulations as well as dietary fibers that modulate the gut microbiome to confer protection against food antigens, enabling doctors to treat patients suffering from life-threatening food allergies effectively.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2016
- Employees
- 9
- Website
- clostrabio.com/
- Ownership
- Privately Held (backing)
ClostraBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClostraBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClostraBio in its N-PORT filings yet. We sweep new filings monthly.